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A B S T R A C T
Cytogenetic abnormalities seen at presentation of acute lymphoblastic leukemia or lymphoblastic lymphoma (ALL/
LBL) are associated with distinct clinical and hematologic disease entities. T-ALL/LBL are morphologically indistin-
guishable from those of B-ALL/LBL. An abnormal kariotype is found in 50–70% of cases of T-ALL/LBL. We present a
35-year old male patient with T-ALL/LBL and t(8;14)(q24;q11.2). Our patient presented with B-symptoms, bulky media-
stinal disease and CNS infiltration. Bone marrow was morphologically normal and cytogenetically without clonal aber-
rations. Cytological findings of the supraclavicular lymph node showed numerous CD3 positive (100%) and CD2 posi-
tive (88%) lymphoblasts, negative for CD34 and CD10. Flow cytometry of lymph node revealed T cell phenotype of im-
mature cells: CD45+CD2+CD5+CD7+CD4+CD8+CD3cyt +CD3TdT+CD10-CD34-HLAD/DR-. Cytogenetic analysis
of lymph node showed translocation t(1;4)(p32;p12), t(8;14)(q24;q11.2). Southern blot analysis of extracted DNA from
the supraclavicular lymph node demonstrated clonal rearrangement of the T cell antigen receptor (TCR/J) gene (region
Vb+Jb2). Based on these findings, diagnosis of T lymphoblastic non Hodgkin lymphoma was established. Cerebrospinal
fluid analysis showed CNS infiltration with 49% lymphoblasts positive for CD4 and CD8. The disease progressed rap-
idly with poor response to therapy. T-ALL/LBL with an unusual t(8;14)(q24;q11.2) is a very rare hematologic disorder
with rapid disease progression and poor response to conventional therapy because of frequent central nervous system in-
volvement and early relapses.
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Introduction
The term »lymphoblastic lymphoma« was recognized
first in 1905 by Sternberg who reported a case of malig-
nant lymphoma involving the mediastinum which termi-
nated in acute leukemia1. T-lymphoblastic lymphoma
(T-LBL) is a rare subtype of adult high-grade non-Hodg-
kin lymphoma (NHL) with an incidence of approximately
2%. Lymphoblastic lymphoma (LBL) and acute lympho-
blastic leukemia (ALL) have been grouped together into
a single entity in the new WHO classification of hema-
tologic malignancies2,12. Even though, lymphoblasts are
precursors of T or B lymphocytes, approximately 85–90%
of lymphoblastic lymphomas (LBL) in adults are of T-cell
phenotype; morphologic, immunophenotypical and mo-
lecular similar to ALL. In some previous studies, the clin-
ical distinction between LBL and ALL has varied and
most centers have used the degree of bone marrow infil-
tration or the presence of leukemic involvement of the
peripheral blood to determine a cut-off between these en-
tities (patients with more than 25% bone marrow in-
volvement are generally classified as T-ALL)2,4.
Cytological and histological features of LBL and ALL
are very similar2,3. In smears, the cells are of medium
size with a high nuclear/cytoplasmic ratio; there may be
a considerable size range from small lymphoblasts with
very condensed nuclear chromatin and no evident nucle-
oli to larger blasts with finely dispersed chromatin and
relatively prominent nucleoli. The number of mitotic fig-
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ures is reported to be higher in T-ALL than B-ALL. T
lymphoblasts frequently show focal acid phosphatase ac-
tivity in smear and imprint preparations, though it is not
specific.
Typical flow cytometric findings for B-lymphoblastic
lymphoma are as follows: CD19+, CD10 bright, CD20+/–,
CD22+/–, TdT+, HLA-DR+, CD34+/–, slg–. Findings for
T-lymphoblastic lymphoma are as follows: sCD3–, but
CD3+, CD4+/CD8+ or CD4– CD8–, CD2+/–, CD5+/–, CD7+/–,
TdT+, CD34+/–, CD10+/–3,4.
Clinical and biological features of T-LBL such as male
predominance (adults between 20 to 40 years), high inci-
dence of mediastinal tumor, and other lymphomatous
manifestations are similar to those of T-ALL and differ-
ent from B-LBL, often with bone marrow and central
nervous system involvement4.
T-ALL and T-LBL are separated by an arbitrary mar-
gin of 25% bone marrow involvement; patients with
higher degree of bone marrow infiltration are generally
classified as T-ALL. As far as treatment is concerned, a
similar approach is used both for T-ALL and T-LBL. It is
now widely accepted that LBL and ALL represent differ-
ent manifestations of the same disease4.
Cytogenetic studies on acute lymphoblastic leukemias
have led to the identification of recurrent abnormalities
specific to ALL, and abnormalities which are independ-
ent prognostic factors5. A variety of chromosomal trans-
locations can occur in T-cell acute lymphoblastic lym-
phoma/leukemia.
We describe a case of 35-year old male with T-lympho-
blastic Non Hodgkin lymphoma and an unusual finding
of t(8;14)(q24;q11.2).
Case Report
A 35 year old male was admitted to our Hematology
Department in November 2008.
Three weeks before admission he noticed raised body
temperature, night sweats, skin itching, pain in left
shoulder and weakness of his left arm and a week later,
cough, chest pain and dyspnea. Patient was then referred
to a regional medical center for imaging studies.
CT scan of the chest showed expansive mass in ante-
rior and middle mediastinum. In view of these imaging
studies, the patient was referred to a tertiary care center
for further work up.
Transbronchal cytology of mediastinal mass showed
non-Hodgkin’s lymphoma-cells. Upon arrival, peripheral
cervical, supraclavicular and axillar lymphadenopathy
was noticed. Laboratory analysis revealed normochromic
normocytic anemia, elevated erythrocyte sedimentation
rate (ESR), lactate dehydrogenase (LDH) and beta 2
microglobulin levels. Coombs tests were negative.
Bone marrow was morphologically normal and cyto-
genetically without clonal aberrations. Cytological find-
ings of the supraclavicular lymph node (Figure 1a) sho-
wed 100% CD3 (Figure 1b) and 88% CD2 positive (Figure
1c) cells, negative for CD34 and CD10. Flow cytometric
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Fig. 1. T-lymphoblastic leukemia in lymph node smears: (a) May-Grünwald-Giemsa staining (b) strong CD3 and (c) CD 2
(d) immunopositivity (LSAB), and cytospin smear of cerebrospinal fluid – May-Grünwald-Giemsa staining.
analysis of lymph node showed T cell phenotype of imma-
ture cells: CD45+CD2+CD5+CD7+CD4+CD8+ CD3cyt+
CD3TdT+CD10-CD34-HLAD/DR-.
Conventional cytogenetic (Figure 2a) and FISH anal-
ysis (Figure 2b) of lymph node showed translocation
t(1;4)(p32;p12) and t(8;14)(q24;q11.2). Southern blot
analysis of extracted DNA from the supraclavicular ly-
mph node demonstrated clonal rearrangement of the T
cell antigen receptor (TCR/J) gene (region Vb+Jb2). Ex-
amination demonstrated T lymphoblastic Non Hodgkin
lymphoma.
Cerebrospinal fluid analysis showed CNS infiltration
with 49% lymphoblasts (Figure 1d) positive for CD4 and
CD8.
An intensive multiagent chemotherapy regimen hy-
per-CVAD, has been administered in three courses from
November 2008 until January 2009. It alternated cyclo-
phosphamide, vincristine, doxorubicin and dexametha-
sone with high doses of methotrexate and cytarabine.
Supportive care apart from the usual measures for
chemotherapy such as sufficient fluid uptake and anti-
emetic treatment included antimicrobial prophylaxis with
a quinolone (500 mg ciprofloxacin twice daily) and anti-
fungal prophylaxis with 200 mg fluconazole daily. Appro-
priate transfusion support was provided. Packed red
blood cells were given for symptomatic anemia or at he-
moglobin levels below 75 g/L and platelet transfusions
were administered prophylactically for platelet counts
lower than 5´109/L or therapeutically if clinically indi-
cated. Neutropenic febrile episodes generally resulted in
an initiation of broad spectrum parenteral antibiotics.
Filgrastim (600 mcg daily) was initiated approximately
24 hours after completion of intensive courses of chemo-
therapy until absolute neutrophil count (ANC) was hi-
gher than 1´109/L.
Peripheral facial paresis occurred in February 2009
during pancytopenia following third cycle of Hyper-
-CVAD. Diagnostic workup showed regression of the me-
diastinal mass, but CNS infiltration was still present.
A new line of intensive chemotherapy with cyclophos-
phamide, etoposide and clofarabine was administered to-
gether with cranial irradiation (2500cGy/8x). Disease re-
mission has been achieved, with complete regression of
mediastinal infiltrates, clearance of lymphoblasts from
cerebrospinal fluid, normal peripheral blood smear and
marrow biopsy.
Stem cell transplantation from a matched relative do-
nor has been considered, but no donor was found. In
March 2009, the patient presented with painful left testi-
cular swelling. Physical examination was otherwise un-
remarkable. Testicular cytology revealed lymphoblastic
infiltration. A chemotherapy regimen containing fluda-
rabine, cyclophosphamide and dexamethasone (FED)
was administered without success. He was admitted in
May with hyperleucocytosis (more than 100´10/9L leuko-
cytes, 70% of atypical blasts) and died soon thereafter.
Discussion
T cell malignancies are divided into two major groups:
precursor T cell lymphoblastic neoplasms, derived from
maturing thymocytes and peripheral T cell lymphomas
(PTCL) arising from mature post-thymic T cells. PTCL,
altogether accounting for less than 15% of all NHL, com-
prise a number of entities. According to the clinical pre-
sentation of the disease they are classified as dissemi-
nated, predominantly extranodal or cutaneous or predo-
minantly nodal.. In comparison with B-cell malignancies,
T-cell neoplasms are overall characterized by an inferior
treatment outcome. Because of the characteristic proper-
ties of this group of malignancies, both cytologically and
immunologically, a diagnosis of lymphoblastic lymphoma
or leukemia could be made with virtual certainty6,7. The
immunostaining of TdT on paraffin-embedded sections
is a useful method for differentiating lymphoblastic lym-
phoma from other lymphomas. Terminal deoxynucleo-
tidyl transferase (TdT) is a DNA polymerase located in
the cell nucleus which catalyses the polymerization of
deoxynucleotides at the 3’hydroxyl ends of oligo- or poly-
deoxynucleotide initiators without a template. Morpho-
logically, T-lymphoblastic lymphoma is indistinguishable
from L1 ALL6,7. According to definition from new WHO
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Fig. 2. Cytogenetic analysis of lymph node with t(8;14) (q24;q11,2); (a) FISH pattern and (b) detection of t(8;14).
classification, T-lymphoblastic leukemia/lymphoblastic
lymphoma is a neoplasm of lymphoblasts committed to
the T cell lineage, typically composed of small to me-
dium-sized blast cells with scant cytoplasm, moderately
condensed to dispersed chromatin and inconspicuous nu-
cleoli, involving bone marrow (BM) and blood (T acute
lymphoblastic leukemia, T-ALL) or presenting with pri-
mary involvement of thymus, nodal or extranodal sites
(T-acute lymphoblastic lymphoma, T-LBL) as defined in
the French-American-British (FAB) classification of ALL12.
Here we presented a male patient with T-ALL/LBL
with t(8;14)(q24;q11) which is very rare. Prevalence is
0.5 to 1. 3 % among all cases off ALL and about 2%
among T-ALL.
On the molecular point of view, location of 8q24 con-
tains gene c-myc which is juxtaposed with the gene of the
T-cell receptor alpha chain (TCR-alpha), and location
14q11 encodes the genes for T-cell receptor alpha (TCR-
-alpha) and T-cell receptor delta (TCR-delta). Some stud-
ies concluded that this chromosomal translocation seems
to be unique and specific for T-cell malignancy13. Al-
though a sensitive marker for Burkitt lymphoma, c-myc
rearrangements are not specific, as they are occasionally
seen in lymphoblastic lymphoma, B-cell lymphoma and
very aggressive transformed follicular lymphoma9. Cyto-
genetic translocation t(8;14) involving TCR-alpha and
c-myc genes in T-cell malignancies are analogous to vari-
ant t(2;8) and t(8;12) translocations observed in Burkitt
lymphoma, and they may play a role in the evolution of
the leukemic process14. T–cell leukemia bearing a t(8;14)
(q24;q11) translocation, potentially has in vivo func-
tional cytolytic activity. It is not determined whether this
activity contributes to the patient’s clinical condition16.
A Pediatric Oncology Group Study from Kaleen and
colleagues presented clinicopathologic findings and sur-
vival data from 10 patients with B-precursor phenotype
ALL and t(8;14)(q11.2;q32). Their data showed that
t(8;14) does not increase the risk of relapse with these
patients10.
Lange et al. presented fifteen pediatric cases of T-cell
leukemia/lymphoma with a t(8;14)(q24;q11). The esti-
mated prevalence of this abnormality among all cases of
ALL was 1%. There was male predominance, high white
blood cell count (median 95´109/L), central nervous system
infiltration, bulky extramedullar leukemia and T-cell
immunophenotype16. ALL with chromosomal transloca-
tions t(8;14)(q24;q32) and less commonly its variants
t(2;8)(p12;q24) or t(8;22)(q24;q11) is characterized by
the morphology of blast cells, presence of monoclonal
surface immunoglobulins (sIg), and these translocations
lead to rearrangements of the proto-oncogene c-myc, lo-
cated at band 8q24. It predominates in children and ado-
lescents and is less common in adults. There is male pre-
dominance with bulky extramedullary leukemia, central
nervous system infiltration and high white blood cell
count. The disease progress rapidly and response to con-
ventional therapy is poor because of frequent central
nervous system involvement and early relapses8,11,12. Our
patient presented with B-symptoms, bulky mediastinal
disease and CNS infiltration, very similar to previously
described T-ALL.
A variety of therapeutic approaches has been reported
for adult LBL generally not separating B- and T-cell type
and separate results for adult T-LBL were only rarely
presented.
Therapy of lymphoblastic lymphoma and T-ALL with
cytogenetic abnormality t(8;14)(q24;q11) is similar to
regimen used in adult ALL, including CNS prophylaxis
and maintenance therapy4. Since LBL are a rare entity,
treatment remains uncertain and many studies have
done to find suitable chemotherapy protocol. Compared
to B-ALL patients, T-ALL patients have increased risk
for induction failure, early relapse and isolated CNS re-
lapse. In adult protocols, T-ALL is treated similarly to
other types of ALL. Various treatment approaches have
been applied to LBL in adults, including protocols for
high-grade NHL such as CHOP, CHOEP, as well as differ-
ent regimens used for treatment of ALL. These include
the so called Hoelzer, LSA2-L2 modified, Hyper CVAD,
GIMEMA LAL094, Stanford regimen, and others, as
well4.
Hoelzer et al. demonstrated results of study with 45
adult patients with T-LBL treated according to an ALL-
-type regimen. The large majority of patients (91%) was
younger than 50 years, reflecting the generally lower me-
dian age of T-ALL/LBL patients. A mediastinal involve-
ment was evident in 89% of the patients which was
higher than in T-ALL (63%). Clinical picture and labora-
tory values of T-LBL patients were different from T-ALL
in several respects (near to normal peripheral blood val-
ues and rare initial CNS involvement in T-LBL). The
treatment approach was similar to previously reported
successful regimen in childhood T-LBL which was the
strongest evidence for the high effectivity of ALL-type
chemotherapy in T-LBL17.
The focus is usually placed on drugs with particular
effectivity in T-ALL like cyclophosphamide, cytarabine,
intensive use of asparaginase and methotrexate4.
The GMALL study will evaluate the efficacy and
tolerability of treatment for adult T-lymphoblastic lym-
phoma (T-LBL) according to a protocol for acute lympho-
blastic leukemia. Patients receive one year of intensive
cyclical chemotherapy with additional prophylaxis for
central nervous system (CNS) relapse by intrathecal
therapy and cranial irradiation and mediastinal irradia-
tion after induction chemotherapy4.
Both autologous and allogenic transplantation with
normal or reduced intensity conditioning are also often
used as part of treatment strategy.
It is evident that all efforts for improvement of treat-
ment strategies have to be made in frontline therapy
since outcome of relapsed patients with T-LBL is ex-
tremely poor. This indicates the need for morphologic
recognition of this malignant lymphoma regardless of
the presence of nuclear convolution, age of the patient,
and site of presentation.
I. Mandac et al.: T-lymphoblastic Lymphoma with t(8;14)(q24;q11), Coll. Antropol. 34 (2010) 1: 265–269
268
T-lymphoblastic lymphoma and its cytogenetic vari-
ants are hematologic entities which represent a true
challenge both in the diagnostic and therapeutic field.
Newer diagnostic methods have enabled better charac-
terization and recognition of this disease. Although there
is no consensus regarding the optimal therapeutic ap-
proach, aggressive chemotherapy including stem cell
transplantation remains the preferred and most widely
used treatment strategy. Newer therapeutic modalities
that could lead to better prognosis of these patients are
eagerly awaited.
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T-LIMFOBLASTI^NI LIMFOM SA RIJETKOM TRANSLOKACIJOM t(8;14)(q24;q11)
– PRIKAZ SLU^AJA
S A @ E T A K
Citogenetske abnormalnosti koje se javljaju kod akutne limfoblasti~ne leukemije ili limfoblasti~nog limfoma (ALL/
LBL), povezane su s razli~itim klini~kim i hematolo{kim entitetima. T-ALL/LBL je morfolo{ki prepoznatljiv u odnosu
na B-ALL/LBL. Abnormalan kariotip se mo`e na}i u 50–70% slu~ajeva T-ALL/LBL. Prikazujemo slu~aj 35-godi{njeg
bolesnika sa T-ALL/LBL i t(8;14)(q24;q11.2) koji se prezentirao B-simptomima, pro{irenom medijastinalnom bolesti i
infiltracijom CNS-a. Ko{tana sr` je morfolo{ki bila normalna bez klonskih aberacija. Citologija supraklavikularnog
limfnog ~vora opisala je brojne CD3 pozitivne (100%) i CD2 pozitivne (88%) limfoblaste, negativne za CD34 i CD10.
Proto~na citometrija limfnog ~vora pokazala je T-stani~ni fenotip nezrelih stanica: CD45+CD2+CD5+CD7+CD4+
CD8+CD3cyt+CD3TdT+CD10-CD34-HLAD/DR-. Citogenetskom analizom limfnog ~vora na|ena je translokacija
t(1;4)(p32;p12) i t(8;14)(q24;q11.2), a Southern blot analizom ekstrahirane DNA iz supraklavikularnog limfnog klo-
nalno preure|enje TCR/J gena (regija Vb+Jb2). Postavljena je dijagnoza T-limfoblasti~nog ne-Hodgkinovog limfoma.
Analizom likvora na|e se infiltracija CNS-a s 49% limfoblasta pozitivnih na CD4 i CD8. Bolest je brzo napredovala, a
odgovor na terapiju je bio slab. T-ALL/LBL sa neuobi~ajenom t(8;14)(q24;q11.2) je vrlo rijedak hematolo{ki poreme}aj s
brzim napredovanjem bolesti i slabim odgovorom na standardnu terapiju, dijelom i radi ~este zahva}enosti sredi{njeg
`iv~anog sustava i ranog relapsa.
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